AMD Advanced Micro Devices Inc.

AMD EPYCâ„¢ Processors Ecosystem Continues to Grow with Integration into New NVIDIA DGX A100

AMD EPYC™ Processors Ecosystem Continues to Grow with Integration into New NVIDIA DGX A100

New NVIDIA DGX A100 system harnesses PCIe® 4 support, high-core count, and overall performance of 2nd Gen AMD EPYC™ Processors to create the world’s most advanced AI system

SANTA CLARA, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: AMD) today announced the , the third generation of the world’s most advanced AI system, is the latest high-performance computing system featuring 2nd Gen AMD EPYC™ processors. Delivering 5 petaflops of AI performance, the elastic architecture of the NVIDIA DGX A100 enables enterprises to accelerate diverse AI workloads such as data analytics, training, and inference.

NVIDIA DGX A100 leverages the high-performance capabilities, 128 cores, DDR4-3200MHz and PCIe® 4 support from two AMD EPYC 7742 processors running at speeds up to 3.4 GHz¹. The 2nd Gen AMD EPYC processor is the first and only current x86-architecture server processor that supports PCIe® 4, providing leadership high-bandwidth I/O that’s critical for high performance computing and connections between the CPU and other devices like GPUs.

“Only 2nd Gen AMD EPYC processors can provide up to 64 cores and 128 lanes of PCIe 4 interconnectivity in a single x86 data center processor, and we’re excited to see how the power of the NVIDIA DGX A100 system enables the I/O bandwidth to be effectively doubled,” said Raghu Nambiar, corporate vice president, data center ecosystems and application engineering, AMD. “With 2nd Gen AMD EPYC processors, our partners and customers can maximize performance and cost efficiencies in heterogeneous computing, virtualized and hyper converged infrastructure workloads, providing teams with the flexibility and capability to stay at the forefront of innovation.”

“The NVIDIA DGX A100 delivers a tremendous leap in performance and capabilities,” said Charlie Boyle, vice president and general manager, DGX systems at NVIDIA. “The 2nd Gen AMD EPYC processors used in DGX A100 provide high performance and support for PCIe Gen4. NVIDIA has put those features to work to create the world’s most powerful AI system while maintaining compatibility with the GPU-optimized software stack used across the entire DGX family.”

Supporting Resources

  • Learn more about the
  • Become a fan of AMD on
  • Follow AMD on 

About AMD

For more than 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies ― the building blocks for gaming, immersive platforms and the datacenter. Hundreds of millions of consumers, leading Fortune 500 businesses and cutting-edge scientific research facilities around the world rely on AMD technology daily to improve how they live, work and play. AMD employees around the world are focused on building great products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) , , and pages.

AMD, the AMD Arrow logo, EPYC and combinations thereof, are trademarks of Advanced Micro Devices, Inc. PCIe is a registered trademark of PCI-SIG Corporation. Other names are for informational purposes only and may be trademarks of their respective owners.

____________________________________

¹ Max boost for AMD EPYC processors is the maximum frequency achievable by any single core on the processor under normal operating conditions for server systems. EPYC-18

Contact:
Aaron Grabein
AMD Communications
(512) 602-8950
 

Laura Graves
AMD Investor Relations
(408) 749-5467
 
EN
08/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Advanced Micro Devices Inc.

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
ACRS ACLARIS THERAPEUTICS INC.
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ORIC KEROS THERAPEUTICS
ZNTL ORIC PHARMACEUTICALS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PLTK SANA BIOTECHNOLOGY
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
EWTX PEPGEN INC
SLDB EDGEWISE THERAPEUTICS INC
DDI SOLID BIOSCIENCES INC
APGE DOUBLEDOWN INTERACTIVE CO LTD
EMBRAC B APOGEE THERAPEUTICS INC
DNTH EMBRACER GROUP AB
ORKA DIANTHUS THERAPEUTICS INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
IMA JADE BIOSCIENCES INC
IMAGENEBIO INC.
Pierre FerraguÊ
  • Pierre FerraguÊ

The Tech Infrastructure Quarterly Bible 4Q25

​​​​We publish today our comprehensive quarterly bible: 243 pages of detailed analyses on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides:

ResearchPool Subscriptions

Get the most out of your insights

Get in touch